Hi Monkeys,
I was taught that PE firms use EBITDA multiple to determine purchase and exit price. But in the real world, do you use other multiples?
1. Why don't you use P/E? You make payment for equity, and receive equity value in the end anyway.
2. Would you use EBIT multiple instead if you purchased a manufacturing target?
What's an exit multiple?
| +106 | Is Everyone Too Bearish on PE? | 34 | 1d |
| +48 | Why would anyone do PE in long term in 2026? | 13 | 2d |
| +36 | MF Tech PE 2026 | 8 | 1h |
| +24 | Q&A: What It’s Actually Like Working at an Independent (Fundless) Sponsor | 4 | 3d |
| +22 | Do you think PE has actually helped you become a better entrepreneur? | 8 | 21h |
| +21 | UMM PE or High Paying Strat Finance? | 13 | 1d |
| +21 | Striking out in last rounds | 2 | 5d |
| +16 | Portfolio Marks | 8 | 18h |
| +15 | Overwhelmed by amount of data / granularity | 3 | 2d |
| +15 | DELETE | 1 | 2d |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Earning dependent on current financing structure which is irrelevant in LBO. After LBO earnings can be negative so both not great metrics for valution in this case.
Yes. Or EBIT - (maintenance) capex. You don't want to include amortization as all costs releated to generate cash from the goodwill are already included in EBIT (no capex required to maintain goodwill if you get what I mean.
Thanks for sharing your insight.
So my understanding is that, using P/E usually assumes the target has a relatively stable capital structure, but that's not the case in LBO because the PE firm will replace the current structure with a new one and the interest expense and hence the earning can be greatly impacted. Not sure if I'm bad at understanding..
When I worked at a PE, banks did send pitchbooks to us with P/E used in comparable analyses though. We didn't pay much attention to that nevertheless. And all banks, including BBs, only used EBITDA multiple for LBO analysis when the target was a heavily capital-intensive pharma. Not sure why it was the case.
And would you use multiples like EV/Sales?
Molestias vero et eum aut. Et voluptas incidunt assumenda numquam enim. Voluptatem esse perferendis animi quam nam eaque est.
Non repellendus eveniet cum fugit quisquam at aut id. Esse eos libero velit mollitia culpa sed velit. Provident aut temporibus voluptates.
Quae facilis aut nulla. Nihil facere ipsum nobis enim eaque autem ut. Nostrum et accusamus eveniet nihil. Est accusantium mollitia consequatur et reiciendis.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...